Soleno Therapeutics (SLNO) Income from Non-Controlling Interests (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$2.2 million in Q1 2026.

• On a quarterly basis, Income from Non-Controlling Interests fell 1500.72% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$2.0 million, a 726.61% decrease from a year earlier, with the FY2025 full-year figure at $37000.0, down 89.75% from the prior year.
• Income from Non-Controlling Interests for Q1 2026 stood at -$2.2 million, down from $68000.0 in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for SLNO reached as high as $1.0 million in Q3 2024 and fell as low as -$2.2 million in Q1 2026.
• Historically, Income from Non-Controlling Interests has averaged -$203000.0 across 3 years, with a median of -$105000.0 in 2024.
• Across the five-year window, Income from Non-Controlling Interests surged 112.66% in 2025 and sank 1500.72% in 2026, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at -$537000.0 in 2024, then jumped by 112.66% to $68000.0 in 2025, then sank by 3372.06% to -$2.2 million in 2026.
• Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$2.2 million in Q1 2026, $68000.0 in Q4 2025, and $261000.0 in Q3 2025.